Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Максимальная стартовая антимикробная терапия нозокомиальной пневмонии уменьшает атрибутивную летальность у больных с тяжелой травмой
Максимальная стартовая антимикробная терапия нозокомиальной пневмонии уменьшает атрибутивную летальность у больных с тяжелой травмой
Д.Н.Проценко, А.И.Ярошецкий, О.В.Игнатенко, Б.Р.Гельфанд. Максимальная стартовая антимикробная терапия нозокомиальной пневмонии уменьшает атрибутивную летальность у больных с тяжелой травмой. Consilium Medicum. Хирургия (Прил.). 2009; 1: 3-7.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Vincent J-L. European Prevalence of Infection in Intensive Care. EPIC II study. 28th ISICEM, 2008.
2. Vincent JL et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Commit- tee. JAMA 1995; 274 (8): 639–44.
3. Bercault N, Boulain T. Mortality rate attributable to ventilator- associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29 (12): 2303–9.
4. Bregeon F et al. Is ventilator-associated pneumonia an indepen- dent risk factor for death? Anesthesiology 2001; 94 (4): 554–60.
5. Papazian L et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996; 154 (1): 91–7.
6. Antonelli M et al. De-escalation antimicrobial chemotherapy in critically III patients: pros and cons. J Chemother 2001; 1 (1): 218–23.
7. Kollef MH et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129 (5): 1210–8.
8. Craven DE et al. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 2009; 135 (2): 521–8.
9. Yaroshetskiy A, Protsenko D. Strategy of antimicrobal therapy in patients with severe trauma: importance of initial severity state eval- uation. Critical Care 2005; 9 (Suppl. 1): 21.
10. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31 (Suppl. 4): S131–8.
11. Depuydt PO et al. Antimicrobial resistance in nosocomial blood- stream infection associated with pneumonia and the value of sys- tematic surveillance cultures in an adult intensive care unit. Crit Care Med 2006; 34 (3): 653–9.
12. Gilbert DN, Beam TR, Kunin CM. The implications for Europe of revised FDA guidelines for clinical trials with anti-infective agents. Eur J Clin Microbiol Infect Dis 1990; 9 (7): 552–8.
2. Vincent JL et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Commit- tee. JAMA 1995; 274 (8): 639–44.
3. Bercault N, Boulain T. Mortality rate attributable to ventilator- associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29 (12): 2303–9.
4. Bregeon F et al. Is ventilator-associated pneumonia an indepen- dent risk factor for death? Anesthesiology 2001; 94 (4): 554–60.
5. Papazian L et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996; 154 (1): 91–7.
6. Antonelli M et al. De-escalation antimicrobial chemotherapy in critically III patients: pros and cons. J Chemother 2001; 1 (1): 218–23.
7. Kollef MH et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129 (5): 1210–8.
8. Craven DE et al. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. Chest 2009; 135 (2): 521–8.
9. Yaroshetskiy A, Protsenko D. Strategy of antimicrobal therapy in patients with severe trauma: importance of initial severity state eval- uation. Critical Care 2005; 9 (Suppl. 1): 21.
10. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000; 31 (Suppl. 4): S131–8.
11. Depuydt PO et al. Antimicrobial resistance in nosocomial blood- stream infection associated with pneumonia and the value of sys- tematic surveillance cultures in an adult intensive care unit. Crit Care Med 2006; 34 (3): 653–9.
12. Gilbert DN, Beam TR, Kunin CM. The implications for Europe of revised FDA guidelines for clinical trials with anti-infective agents. Eur J Clin Microbiol Infect Dis 1990; 9 (7): 552–8.
Авторы
Д.Н.Проценко, А.И.Ярошецкий, О.В.Игнатенко, Б.Р.Гельфанд
Кафедра анестезиологии и реаниматологии ФУВ Российский государственный медицинский университет, Городская клиническая больница №7, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.